ストックスクリーナーアプリを入手
14.10
2.96%
-0.43
アフターアワーズ：
13.90
-0.20
-1.42%
前日終値:
$14.53
開ける：
$14.22
24時間の取引高:
2.74M
Relative Volume:
0.53
時価総額：
$4.37B
収益：
-
当期純損益:
$-127.69M
株価収益率:
-31.28
EPS:
-0.4508
ネットキャッシュフロー:
$-98.43M
1週間 パフォーマンス:
+3.60%
1か月 パフォーマンス:
+33.21%
6か月 パフォーマンス:
+886.01%
1年 パフォーマンス:
+1,002%
1日の値動き範囲:
$13.84
$14.63
1週間の範囲:
$12.84
$14.63
52週間の値動き範囲:
$1.01
$14.63
Erasca Inc Stock (ERAS) Company Profile
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
14.10 | 4.50B | 0 | -127.69M | -98.43M | -0.4508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 再開されました | Mizuho | Outperform |
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-10-16 | 開始されました | Stifel | Buy |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-08-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 開始されました | Raymond James | Outperform |
| 2024-11-18 | 開始されました | Jefferies | Buy |
| 2024-03-11 | 開始されました | CapitalOne | Overweight |
| 2024-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-30 | 開始されました | Mizuho | Buy |
| 2023-02-24 | 開始されました | Goldman | Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Erasca Inc (ERAS) 最新ニュース
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Erasca, Inc. (ERAS): A Bull Case Theory - Yahoo Finance
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 - Yahoo Finance
ERAS: Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024 - TradingView
ERAS: Lead RAS-targeted therapies show promising early results, with key clinical updates expected in 2024 - TradingView
Erasca, Inc. (ERAS) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Pipeline - DirectorsTalk Interviews
Erasca Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Erasca (NASDAQ:ERAS) Hits New 12-Month HighHere's What Happened - MarketBeat
Erasca stock hits 52-week high at $13.30 - Investing.com
Erasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors - marketscreener.com
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 - Bitget
New Erasca patent protects ERAS-4001 for RAS-driven cancers to 2043 - Stock Titan
Will Erasca Inc. outperform small cap indexes2025 Pullback Review & AI Optimized Trading Strategy Guides - mfd.ru
Setup Watch: How does Erasca Inc perform in inflationary periods2025 Major Catalysts & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Erasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Erasca (NASDAQ:ERAS) Sets New 12-Month HighShould You Buy? - MarketBeat
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
ERAS PE Ratio & Valuation, Is ERAS Overvalued - Intellectia AI
Can Erasca Inc. stock deliver consistent earnings growthJuly 2025 Retail & Free Technical Pattern Based Buy Signals - mfd.ru
Assessing Erasca (ERAS) Valuation After Early Clinical Signals And Strong Share Price Momentum - Sahm
Can Erasca Inc. stock beat market expectations this quarter2025 Volume Leaders & Daily Profit Maximizing Trade Tips - mfd.ru
ERAS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat - MarketBeat
Erasca stock today: ERAS rises as traders parse Guggenheim biotech talk, eye next data - Bez Kabli
Will Erasca Inc. be affected by tariffsJuly 2025 Volume & Verified Stock Trade Ideas - mfd.ru
Erasca stock reaches 52-week high at 12.48 USD By Investing.com - Investing.com South Africa
Erasca (NASDAQ:ERAS) Trading Up 6.8%Should You Buy? - MarketBeat
Erasca stock reaches 52-week high at 12.48 USD - Investing.com
ERAS: Early clinical data show promising efficacy and safety for next-generation pan-RAS and pan-KRAS inhibitors - TradingView
What analysts say about Erasca Inc. stockInsider Selling & Free Growth Oriented Trading Recommendations - mfd.ru
Will Erasca Inc. stock go up in YEARTrade Risk Report & Proven Capital Preservation Tips - mfd.ru
Erasca Sees Unusually High Options Volume (NASDAQ:ERAS) - MarketBeat
What sentiment indicators say about Erasca Inc. stock2025 Growth vs Value & Weekly Breakout Watchlists - mfd.ru
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target - Investing.com Australia
Erasca (NASDAQ:ERAS) Sets New 1-Year HighStill a Buy? - MarketBeat
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target By Investing.com - Investing.com South Africa
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - MSN
Erasca (ERAS) Is Up 15.2% After Upsized Offering Extends Cash Runway For RAS/MAPK Pipeline - simplywall.st
Erasca (NASDAQ:ERAS) Trading 6.4% HigherHere's What Happened - MarketBeat
Erasca to Present at Upcoming Conferences in February - The Manila Times
Erasca (ERAS) Price Target Increased by 60.94% to 10.51 - Nasdaq
Erasca (ERAS) Is Up 10.4% After $225M Follow-On Offering And RAS Pipeline UpdatesHas The Bull Case Changed? - Yahoo Finance
Erasca (NASDAQ:ERAS) Hits New 52-Week HighStill a Buy? - MarketBeat
Erasca stock hits 52-week high at $10.71 By Investing.com - Investing.com Nigeria
Erasca stock hits 52-week high at $10.71 - Investing.com India
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock? - Barchart.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Mizuho initiates Erasca (ERAS) with 'outperform' rating and $16 PT - MSN
Mizuho Initiates Erasca (ERAS) With 'Outperform' Rating and $16 PT - Finviz
Erasca Inc (ERAS) 財務データ
収益
当期純利益
現金流量
EPS
5.71%
0.02%
大文字化:
|
ボリューム (24 時間):